Reported 3 days ago
Investment firms Carlyle Group and SK Capital have finalized a tender offer to acquire bluebird bio, Inc. for either $3 per share with additional contingent value rights or $5 per share in cash. The merger is expected to be completed on June 2, 2025, following regulatory approvals. This acquisition comes as bluebird bio faces financial challenges, including a high debt-to-capital ratio.
Source: YAHOO